MONDAY DEADLINE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - WGS

Purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive, have until Monday, August 3, 2026, to seek appointment as lead plaintiff of the class action lawsuit. The lawsuit charges GeneDx and certain of its executive officers with violations of the Securities Exchange Act of 1934. GeneDx is a genomics company that provides genetic testing services. On April 16, 2025, GeneDx announced an agreement to acquire Fabric Genomics, a firm focused on AI-driven genomic interpretation. The lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose significant problems in Fabric Genomic's viability that would negatively impact GeneDx's overall business and operations. On May 4, 2026, GeneDx announced its first quarter results, revealing a drop in adjusted gross margin from 74% to 69%, reduced projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss directly attributable to Fabric Genomics. On this news, the price of GeneDx stock dropped over 49%.

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased GeneDx common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.